- +91 99000 79030
- info@spashtahealthcare.com
- Off Bannerghatta Road, Bengaluru
Cancer care is not just about treating a disease — it is about understanding the person behind the diagnosis. At Spashta Healthcare, Dr. Sneha Kommineni combines precision diagnostics, personalised treatment planning, and compassionate guidance to help patients navigate every stage of their cancer journey with clarity and confidence.
Dr. Sneha Kommineni is a Consultant Medical Oncologist (MBBS, MD, DNB — Medical Oncology, MRCP SCE UK) with particular expertise in targeted therapy for solid and haematological malignancies. She completed her MBBS at Siddhartha Medical College, Vijayawada, her MD at Pramukhswami Medical College under Sardar Patel University, Gujarat, and holds the Specialty Certificate Examination (SCE) from the Royal College of Physicians, UK.
In addition to her practice at Spashta Healthcare, Dr. Sneha is available for consultations by prior appointment at Aster RV and Aster Whitefield.
Cancer treatment is rarely about choosing a single drug or a single procedure. It involves understanding the biology of the disease, the patient’s overall health, family circumstances, long-term goals, and quality of life. Dr. Sneha’s approach combines evidence-based oncology with personalised treatment planning, ensuring that every recommendation is both scientifically sound and individually appropriate.
Her clinical philosophy is built around three convictions: every cancer is different, every treatment should be shaped by that difference, and the quality of life a patient lives during and after treatment matters as much as the treatment itself. She is known among her patients for the depth of her explanations, her willingness to sit through difficult conversations without rushing, and her insistence on making sure every treatment decision is understood — not just accepted.
Consultant Medical Oncologist MBBS, MD, DNB (Medical Oncology), MRCP SCE (UK)
Siddhartha Medical College, Vijayawada
Pramukhswami Medical College, Sardar Patel University, Gujarat
Medical Oncology
Royal College of Physicians, United Kingdom
Targeted Therapy for Solid and Hematological Malignancies
Aster RV and Aster Whitefield, Bengaluru
The way cancer is treated has changed fundamentally in the last decade. Where oncologists once chose therapies primarily based on the type and stage of cancer, today the most effective treatment decisions are driven by the molecular and genetic profile of the tumour itself. Two patients with what appears to be the same cancer on a scan may, at the molecular level, have two entirely different diseases — and they deserve two entirely different treatment plans.
Dr. Sneha practises this precision-led approach as the foundation of her oncology care, not as an add-on.
Genetic and molecular testing of the tumour itself reveals the specific mutations driving a patient's cancer. This information helps identify which targeted therapies are likely to be effective, which treatments may provide limited benefit, and whether specialised treatment pathways or clinical trials should be considered. By understanding the biological drivers of a tumour rather than relying solely on its location, treatment can be tailored with far greater precision. Dr. Sneha incorporates tumour genomic profiling into routine care wherever it is clinically meaningful.
Next-generation sequencing is a comprehensive genomic analysis that examines large sections of a tumour's DNA in a single test, identifying actionable mutations and resistance markers that conventional testing may miss. For complex cancers, rare cancers, and situations where first-line treatment has not produced the expected response, NGS can uncover treatment opportunities that would otherwise remain hidden. It provides a deeper understanding of the tumour's biology and often helps guide more informed treatment decisions.
A liquid biopsy is a blood test that detects fragments of tumour DNA circulating in the bloodstream. It can be used to identify mutations, monitor how the cancer is responding to treatment, and detect early signs of recurrence — often before any change is visible on imaging. For patients in whom a tissue biopsy is difficult, risky, or impractical to repeat, liquid biopsy offers a valuable alternative. It also provides an additional tool for ongoing monitoring throughout the cancer journey.
Molecular reports are only as valuable as the clinical interpretation that surrounds them. Before Dr. Sneha finalises a treatment plan based on genomic findings, she ensures that the results are reviewed within a multidisciplinary framework — incorporating inputs from pathology, radiology, surgical oncology, and radiation oncology whenever relevant. The goal is not simply to generate more data, but to translate that data into practical, patient-centred decisions.
Two patients with the same cancer on a scan can have completely different diseases at the molecular level. Precision oncology — using genomic profiling, NGS, and liquid biopsy — is the difference between a treatment aimed at the disease and a treatment aimed at your disease.
Once the diagnosis and molecular profile are clear, Dr. Sneha builds a treatment plan that is specific to the patient — not just the cancer. That plan may draw on one or more of the following therapies, often in combination, and always with the patient’s overall health, preferences, and life circumstances taken into account.
Chemotherapy remains a foundational tool in cancer treatment and continues to play an important role across many cancer types. Dr. Sneha provides both oral chemotherapy (tablet-based regimens that can often be taken at home) and intravenous chemotherapy (infusion-based treatments), while closely monitoring progress and managing side effects. Each treatment plan is tailored to the patient's diagnosis and overall health, ensuring therapy is delivered as safely, effectively, and comfortably as possible.
Targeted therapies are drugs designed to act on specific molecular features of a cancer — the mutations, proteins, or pathways that drive a particular tumour. Because they are directed at the biological mechanisms fuelling the disease, they can often produce meaningful results while minimising unnecessary damage to healthy tissue. Dr. Sneha prescribes targeted therapy for both solid tumours and haematological malignancies whenever molecular testing identifies a clinically relevant target.
Immunotherapy works differently from traditional cancer treatments. Rather than attacking the cancer directly, it helps the patient's own immune system recognise and destroy cancer cells more effectively. For certain cancers, immunotherapy has transformed outcomes that were once considered limited, offering new possibilities for long-term disease control. Dr. Sneha incorporates immunotherapy into treatment plans where it is clinically appropriate and supported by the patient's tumour characteristics and molecular profile.
The most important decision in a cancer journey is rarely a single drug — it is the overall treatment strategy. How to sequence therapies. Which treatments to combine. When to continue, pause, or change direction. How to balance effectiveness with quality of life and side-effect management. Dr. Sneha develops treatment plans collaboratively with each patient, combining clinical evidence, molecular insights, and individual circumstances to create a plan that is both medically sound and personally appropriate.
The best cancer treatment is the one never needed — because the cancer was prevented or detected so early that a full cure was possible. Prevention and early detection are not secondary concerns in Dr. Sneha’s practice; they are a core part of how cancer care is approached. By identifying risk early and intervening appropriately, many cancers can either be prevented altogether or diagnosed at a stage when treatment is far more effective.
Not every person needs every screening test, and not every screening programme should begin at the same age. Dr. Sneha recommends structured cancer screening based on age, gender, family history, lifestyle factors, and individual risk profiles. Screening strategies may include breast, cervical, colorectal, and other common cancers, ensuring that testing is both appropriate and clinically meaningful. The goal is to detect disease at its earliest and most treatable stage while avoiding unnecessary investigations.
Some of the most effective cancer prevention tools available today are vaccines. The HPV vaccine significantly reduces the risk of cervical, throat, and several other cancers, while the Hepatitis B vaccine reduces the risk of liver cancer. Despite strong scientific evidence supporting their effectiveness, vaccination rates remain lower than they should be. Dr. Sneha strongly advocates preventive vaccination, particularly for younger adults and families, as part of a long-term cancer prevention strategy.
Some cancers occur because of inherited genetic mutations that can be identified before disease develops. Hereditary cancer gene testing for conditions such as BRCA1/2-related cancers, Lynch syndrome, and other hereditary cancer syndromes helps identify individuals who may be at elevated risk. This information allows for enhanced surveillance, preventive interventions, and informed healthcare decisions for both patients and their families. Dr. Sneha provides careful counselling before and after testing to ensure results are understood in the right clinical context.
Advances in cancer diagnostics are creating new opportunities for earlier detection than ever before. Blood-based early detection assays are designed to identify molecular signals of cancer from a simple blood sample, potentially before symptoms develop or imaging abnormalities become visible. As these technologies continue to evolve, they represent one of the most promising areas in cancer prevention and early diagnosis. Spashta Healthcare is preparing to integrate these innovations into clinical practice as they become validated and widely available.
For many patients, the end of active treatment is not the end of the cancer journey. It is the start of a new phase — one that can bring its own uncertainties, physical changes, and emotional complexity. Dr. Sneha is known for the depth with which she attends to this phase of care, which is too often treated as an afterthought.
Cancer treatments can leave behind long-term effects — on the heart, kidneys, nerves, bones, hormones, or fertility — that need structured monitoring long after the last dose is given. Dr. Sneha builds toxicity surveillance into every survivorship plan, catching problems early and managing them proactively.
For high-risk patients, structured follow-up is essential for detecting any recurrence at the earliest, most treatable stage. Dr. Sneha develops personalised surveillance plans using imaging, laboratory testing, and biomarker monitoring to identify concerning changes early and guide timely intervention when needed.
Returning to normal after cancer is rarely a straight line. It involves physical rebuilding, emotional reconstruction, and often a reassessment of priorities. Dr. Sneha supports patients through structured lifestyle modification — nutrition, activity, sleep, and stress management — as a clinical part of recovery, not an optional extra.
Anxiety, low mood, fear of recurrence, and survivor guilt are common and real. They are not signs of weakness. Dr. Sneha addresses the psychological dimension of survivorship openly and, where specialist support is needed, connects patients with appropriate counselling and peer support.
Palliative care is not end-of-life care. It focuses on relieving symptoms, reducing discomfort, and improving quality of life alongside active treatment. Dr. Sneha integrates supportive care whenever needed, ensuring patients receive compassionate symptom management throughout their cancer journey.
For long-term cancer survivors, a second, unrelated cancer can develop years after the first. Dr. Sneha carefully evaluates prior treatments, long-term effects, and accumulated toxicities to design safe, effective treatment plans tailored to each survivor’s unique medical history.
Many patients come to Dr. Sneha not because they are newly diagnosed, but because they are already undergoing treatment and want clarity on one important question: is this the right plan?
This is a reasonable and important question, and one that Dr. Sneha takes seriously. She reviews previous reports, imaging studies, pathology findings, and treatment history in detail before providing a clear and objective assessment. That assessment may confirm the current approach, suggest refinements, or identify alternative options worth considering.
Her goal is never to override another clinician. It is to ensure that every patient understands their treatment plan, feels confident in the decisions being made, and can move forward with trust and clarity.
Precision oncology means choosing cancer treatment based on the specific molecular and genetic profile of a tumor, rather than only on its type and stage. Two patients with what looks like the same cancer can respond very differently to the same drug, depending on the mutations driving their disease. Precision oncology is the difference between a treatment aimed at the disease and one aimed at your disease.
Chemotherapy is a broad treatment that attacks rapidly dividing cells. Targeted therapy is aimed precisely at the molecular features driving a specific cancer — so it tends to affect cancer cells more and healthy cells less. Immunotherapy works by training the patient’s own immune system to attack the cancer. Modern treatment plans often combine these approaches rather than choosing one.
Yes — and this is one of the most common reasons patients come to her. Dr. Sneha reviews your prior reports, imaging, and treatment details, and provides a clear, honest assessment of the current plan and any alternative options. The goal is to give you confidence in your path, whatever that path looks like.
A regular biopsy involves taking a tissue sample, usually through a needle or a surgical procedure. A liquid biopsy is a blood test that detects fragments of tumor DNA circulating in the bloodstream — no tissue needed. It is useful for identifying mutations, monitoring treatment response, and detecting early signs of recurrence, often before any change appears on a scan.
It is worth considering if you have a strong family history of cancer — especially breast, ovarian, colorectal, or uterine cancer — or if cancers in your family developed at unusually young ages. Dr. Sneha will take a detailed family history and advise whether testing is clinically appropriate, with proper counselling before and after.
HPV vaccination is most effective when given before sexual activity begins, but it can still offer meaningful protection in adults — particularly young adults up to the mid-forties, and in certain clinical situations beyond that. Dr. Sneha will advise based on your age, exposure history, and current health.
Spashta Healthcare is a super specialty OPD clinic for consultation, treatment planning, follow-up, and survivorship care. Intravenous chemotherapy infusions, advanced imaging, surgery, and radiation therapy happen at partner hospital settings, where Dr. Sneha coordinates your carefully. Many patients find it significantly easier to have their ongoing consultations and oral therapy follow-ups at the neighborhood clinic, with hospital visits reserved only for specific interventions.
A first consultation is unhurried. Dr. Sneha reviews your history, any prior reports and scans, your family history, and your personal concerns. She explains what is known, what is still unclear, what tests may be needed next, and what the likely treatment paths are. You will not be rushed, and you will not leave with unanswered questions.
Spashta Healthcare is located in BTM Layout, off Bannerghatta Road — conveniently accessible from HSR Layout, Jayanagar, JP Nagar, Koramangala, Bommanahalli, Hongasandra, Bilekahalli, Hulimavu, Arekere, Sarjapur Road, and across South and Central Bengaluru.
Evening and off-hours appointments are available — because cancer conversations should not be squeezed into a working lunch break. You get the time, the attention, and the clinical depth that a cancer journey actually needs.
